Figure 3

Unsupervised PCA of D0 (triangle) and M1 (circle) patient samples, and MFs demonstrating a decrease in abundance after the start of anti-TB treatment. The PCAs were constructed based on MFs present in at least 70% and 50% of the samples for any given time point of Discovery Set-1 (A) and Discovery Set-2 (B), respectively, and that decreased in abundance between D0 and M1 by at least 2 fold with a p < 0.05. A k-means clustering analysis was performed to select MFs that decreased in abundance between D0 and M1 of Discovery Set-1 (C) and Discovery Set-2 (D).